Radiation Oncology

Latest News

October 31st 2020

SBRT Appears to be Superior to CRT for Controlling Pain Related to Spinal Metastases

Stereotactic body radiotherapy may be superior to conventional palliative radiotherapy in improving the complete response rate for pain related to spinal metastases at 3- and 6-months post-radiation.

October 31st 2020

Study Suggests Stereotactic Radiosurgery Become Standard of Care for Patients with 4+ Brain Metastases

By Hannah Slater

December 27th 2016

A Personalized Approach to Radiation Therapy

By John Schieszer

Latest Videos

$Hypofractionated radiotherapy yields less financial toxicity than conventionally fractionated radiotherapy in patients with breast cancer who have undergone reconstruction following mastectomy.$

Hypofractionated RT Improves Specific QOL in Breast Cancer With Reconstruction

$Those with breast cancer who have undergone implant-based reconstruction following mastectomy have similar outcomes with hypofractionated vs conventionally fractionated radiotherapy.$

Data Support Shorter Radiation Course in Breast Cancer With Reconstruction

An expert from Dana-Farber Cancer Institute indicates that urologists should refer patients with prostate cancer who present with multiple high-risk factors at surgery to a radiation and medical oncologist.

Detecting High-Risk Prostate Cancer Factors Can Inform Referral Strategies

Fifteen-year results of the ProtecT prostate cancer trial may support the findings of the study’s 10-year follow-up data, according to an expert from Dana-Farber Cancer Institute.

ProtecT Trial 15-Year Follow-Up May be ‘Very Important’ for Prostate Cancer

Increasing age, higher Gleason scores, and higher pathologic stages are predictors of mortality in patients with prostate cancer, according to an expert from Dana-Farber Cancer Institute.

Other Considerations for Better Long-Term Outcomes in Prostate Cancer

Clinical trials highlight benefits, including radiographic progression-free survival following treatment with radioligand 177Lu-PSMA-617 in pretreated patients with metastatic castration-resistant prostate cancer.

177Lu May Be a ‘Good Choice’ for Pretreated Metastatic Prostate Cancer

Early data from ongoing clinical trials suggest the potential safety and efficacy of novel radium-223 combinations as treatment for metastatic castration-resistant prostate cancer.

Ongoing Trials Suggest Benefits of Radium-223 Combos in Prostate Cancer

Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.

Ongoing Radioligand Trials May ‘Shift the Paradigm’ in Prostate Cancer

An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.

PSA Cut-Point Indicates When to Start Salvage Radiotherapy in Prostate Cancer

Radiation Oncology

Latest News

Latest Videos

Hypofractionated RT Improves Specific QOL in Breast Cancer With Reconstruction

Data Support Shorter Radiation Course in Breast Cancer With Reconstruction

Detecting High-Risk Prostate Cancer Factors Can Inform Referral Strategies

ProtecT Trial 15-Year Follow-Up May be ‘Very Important’ for Prostate Cancer

Other Considerations for Better Long-Term Outcomes in Prostate Cancer

177Lu May Be a ‘Good Choice’ for Pretreated Metastatic Prostate Cancer

Ongoing Trials Suggest Benefits of Radium-223 Combos in Prostate Cancer

Ongoing Radioligand Trials May ‘Shift the Paradigm’ in Prostate Cancer

PSA Cut-Point Indicates When to Start Salvage Radiotherapy in Prostate Cancer

Radium-223 Plays Important Role in Management of Prostate Cancer Subgroup

CME Content

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | New Mexico Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Iowa Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Empire State Hematology and Oncology Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Florida Regional Program

Rhode Island Oncology Society

Community Oncology Connections™: How Can We Optimize the Use of Oral SERDs in the Community Oncology Setting? Best Practices for HR+/HER2– Breast Cancer | North Carolina Oncology Association

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Kentucky Society of Clinical Oncology

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | South Carolina Oncology Society

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma | Texas Society of Clinical Oncology

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | The Arizona Clinical Oncology Society

Tennessee Oncology Practice Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Louisiana Oncology Society

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | New Mexico Society of Clinical Oncology

Texas Society of Clinical Oncology

North Carolina Oncology Association

9th Annual School of Nursing Oncology™

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Community Practice Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Alabama Regional Program

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | North Carolina Oncology Association

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Bridging Academic and Community Connections to Advance Precision and Targeted Care in NF1 Plexiform Neurofibromas | Colorado Oncology Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Illinois Regional Program

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Tennessee Oncology Practice Society

Washington State Medical Oncology Society

Kansas Society of Clinical Oncology

Medical Crossfire®: TKIs and ADCs in HER2-Mutant NSCLC – Which Class, Which Line?

Wyoming State Oncology Society

Montana State Oncology Society

Kentucky Society of Clinical Oncology

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Indiana Oncology Society

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Washington State Medical Oncology Society

Breast Cancer Symposia in San Antonio

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways from Limited-Stage Through Relapsed Disease

Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Iowa Oncology Society

Empire State Hematology & Oncology Society (New York)

Hot Seat: How Experts Are Integrating the Latest Practice-Changing Data Into Their Breast Cancer Clinics

South Carolina Oncology Society

Immunotherapy Across the SCLC Continuum: Optimizing Treatment Pathways From Limited-Stage Through Relapsed Disease | Wisconsin Association of Hematology and Oncology

Community Oncology Connections: Navigating PD-L1–Driven Decisions and ADC Integration in Frontline mTNBC | Missouri Oncology Society

Annual Hematology Meeting Preceding the 68th ASH Annual Meeting and Exposition

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Community Oncology Connections™: Bridging Academic and Community Expertise in Evidence-Based Care for Desmoid Tumors | Nevada Oncology Society

Arizona Clinical Oncology Society

Nevada Oncology Society

Navigating the Adverse Event Landscape in HER2+ GEA Therapy

Missouri Oncology Society

Cases and Conversations: Implementing Recent Updates to Improve Outcomes for Patients With MDS

(CME Track) Tackling Oncologic Emergencies in Patients Treated With High-Dose Methotrexate

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

From Frontline to Heavily Pretreated HR+/HER2- Metastatic Breast Cancer: Expert Perspectives on Optimizing the Expanding Treatment Armamentarium

Diagnosis and Management of TGCT

Optimizing Multidisciplinary Care in TGCT

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

(CPE Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Tumor Board: Translating HER2 and TROP2 Innovations to Transform NSCLC Care